Beata M. M.
- Country
- Poland
- Department
- Oddzial Onkologii Ginekologicznej
Research Overview
- Phase 3 Randomized Open-Label Trial of Tisotumab Vedotin Versus Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
- Evaluation of Bevacizumab Dose Equivalence in First-Line Treatment of Ovarian, Fallopian Tube, and Peritoneal Carcinomas with Olaparib, Carboplatin, and Paclitaxel
- Phase 3 Randomized Open-Label Study of Avutometinib and Defactinib Versus Standard Treatment in Recurrent Low-Grade Serous Ovarian Cancer
Data & Insights
Has run more than one trial at 89 of 222 partner sites.
Specializations
Gynecologic Oncology
Focused on endometrial cancer, ovarian carcinoma, and cervical carcinoma, the investigator leads studies addressing advanced disease, recurrence, and biomarker‑driven therapies.
- Advanced or recurrent endometrial carcinoma
- Platinum‑resistant ovarian cancer
- High‑grade serous ovarian and fallopian tube malignancies
- Locally advanced cervical cancer
Research integrates molecular profiling to refine treatment selection for women with gynecologic malignancies.
Breast Cancer Therapeutics
Extensive activity in HR‑positive, HER2‑negative breast cancer and triple‑negative breast cancer, emphasizing endocrine resistance, targeted combinations, and neoadjuvant strategies.
- Hormone‑receptor positive, HER2‑negative disease
- Triple‑negative breast cancer with PD‑L1 expression
- HER2‑positive early breast cancer
- Adjuvant endocrine therapy optimization
Efforts aim to improve disease‑free survival and pathological complete response rates across breast cancer subtypes.
Immuno‑Oncology
Active participation in trials evaluating checkpoint inhibitors such as pembrolizumab and durvalumab across solid tumors, with a particular focus on immunogenic gynecologic and thoracic cancers.
- Pembrolizumab‑based combinations in endometrial carcinoma
- Durvalumab with chemotherapy in urothelial carcinoma
- Immune‑checkpoint blockade in metastatic NSCLC
- PD‑L1‑targeted therapy in cervical cancer
These studies explore predictive biomarkers and synergistic regimens to enhance antitumor immunity.
Targeted Molecular Therapies
Investigations incorporate agents directed at DNA repair deficiencies, PI3K/AKT/mTOR pathway alterations, and HER2 signaling, reflecting a precision‑medicine approach.
- PARP inhibitor strategies in BRCA‑mutated ovarian cancer
- PI3K‑targeted agents for HR‑positive breast cancer
- HER2‑directed antibody‑drug conjugates in breast and gastric cancers
- Combination of CDK4/6 inhibitors with endocrine therapy
Emphasis is placed on matching molecular alterations with tailored therapeutic options.
Rare and Advanced Solid Tumors
Engagement in studies targeting less common malignancies such as malignant peritoneal neoplasms, nasopharyngeal carcinoma, and high‑grade melanoma, often in the context of novel immuno‑ or targeted agents.
- Peritoneal carcinomatosis with HER2 expression
- Nasopharyngeal cancer refractory to platinum chemotherapy
- Advanced melanoma with mismatch repair proficiency
- Prostate cancer imaging with 68Ga‑PSMA‑11 PET
These efforts broaden therapeutic options for patients with limited standard‑care alternatives.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.